Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8871854 | 0.98 | CHRM2 (0.82) | CHRM2CHRM1 | |
| SCHEMBL194766 | 0.92 | CHRM2 (1.00) | CHRM2CHRM1 | |
| SCHEMBL9369177 | 0.83 | CHRM2 (0.83) | CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL9370350 | 0.81 | CHRM2 (0.81) | CHRM2CHRM1 | |
| SCHEMBL8825098 | 0.80 | CHRM2 (0.85) | CHRM2CHRM1 | |
| SCHEMBL24434493 | 0.80 | CHRM2 (0.56) | CHRM2CHRM1 | |
| SCHEMBL9724682 | 0.80 | CHRM2 (0.56) | CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL9373021 | 0.79 | CHRM2 (0.55) | CHRM2CHRM1 | |
| SCHEMBL9451960 | 0.79 | CHRM2 (0.55) | CHRM2CHRM1 | |
| SCHEMBL8871375 | 0.78 | CHRM2 (0.67) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994009787-A1 | SYNERGISTIC COMBINATION FOR THE THERAPY OF DEGENERATIVE AGEING DISEASES CONTAINING AN ADENOSINE ANTAGONIST AND A CHOLINOMIMETIC | BOEHRINGER INGELHEIM KG (DE) | 1994-05-11 | — | — | WO | claimed |
| EP-0261763-B1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1994-02-09 | — | — | EP | claimed |
| EP-0239309-B1 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME (GB) | 1994-01-12 | — | — | EP | claimed |
| EP-0261763-A1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1988-03-30 | — | — | EP | claimed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9403806-B1 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9174972-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2015-04-09 | — | — | US | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2403340-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-1994009787-A1 | SYNERGISTIC COMBINATION FOR THE THERAPY OF DEGENERATIVE AGEING DISEASES CONTAINING AN ADENOSINE ANTAGONIST AND A CHOLINOMIMETIC | BOEHRINGER INGELHEIM KG (DE) | 1994-05-11 | — | — | WO | disclosed |
| US-4968691-A | TREATMENT AND PREVENTION OF DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1990-11-06 | — | — | US | disclosed |
| EP-0261763-A1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1988-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | CHRM2 4/4885CHRM1 7/4885 |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, CHRM4, CHRM5 | CHRM2 4/4885CHRM1 5/4885 |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | CHRM2 6/4885CHRM1 9/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | CHRM2 6/4885CHRM1 9/4885 |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | CHRM2 4/4885CHRM1 7/4885 |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | CHRM2 4/4885CHRM1 7/4885 |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | CHRM2 6/4885CHRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.